Corrigendum to "Evaluation of the distribution and excretion of [
14
C]-inclisiran following single subcutaneous administration in cynomolgus monkeys" [Toxicology and Applied Pharmacology 443 (2022) 115978]
Toxicol Appl Pharmacol
.
2022 Sep 15:451:116144.
doi: 10.1016/j.taap.2022.116144.
Epub 2022 Jul 1.
Authors
Dario Lehoux
1
,
Adel Rafai Far
2
,
David Kallend
3
,
Peter L J Wijngaard
4
,
Brad Zerler
4
Affiliations
1
Targanta Therapeutics Inc., a wholly owned subsidiary of The Medicines Company, Saint Laurent, Quebec H4S 2A1, Canada.
2
Targanta Therapeutics Inc., a wholly owned subsidiary of The Medicines Company, Saint Laurent, Quebec H4S 2A1, Canada. Electronic address: adel.rafai_far@novartis.com.
3
The Medicines Company (Schweiz) GmbH, Zurich 8001, Switzerland.
4
The Medicines Company Inc., Parsippany, NJ 07054, USA.
PMID:
35780943
DOI:
10.1016/j.taap.2022.116144
No abstract available
Publication types
Published Erratum